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ORIGINAL ARTICLE
Absence of Intraocular Infections after Hematopoietic
Stem Cell Transplantation at a Single Center: The
Experience with Current Preventive Regimens
Elena I. Stoyanova, MD, MSc1, Anjo Riemens, MD1, Henk M. Lokhorst, PhD, MD2,
Liane te Boome, MD2, and Aniki Rothova, PhD, MD1,3
1Department of Ophthalmology, 2Department of Hematology, University Medical Center Utrecht, Utrecht,
The Netherlands, and 3Department of Ophthalmology, Erasmus Medical Center, Rotterdam, The Netherlands
ABSTRACT
Purpose: To investigate the prevalence of intraocular infections after allogeneic stem cell transplantation (allo-
SCT).
Methods: The study design was a single institutional retrospective noncomparative cohort of 135 consecutive
patients in 2006 and 2007 who underwent allo-SCT for hematological malignancy. The primary outcome was
the development of intraocular infections after allo-SCT and secondary outcome consisted of development of
other ocular disorders during follow-up.
Results: The most frequent ocular sequel to allo-SCT included ocular graft-versus-host disease (GvHD), which
developed in 37/135 patients (27%). Intraocular infection occurred in 1 of 135 patients (0.7%). This patient
developed infectious chorioretinitis together with osteomyelitis, endocarditis, and brain abscess with fungus
Scedosporium and was successfully treated with a combination of voriconazole, amphotericine B, and surgical
interventions. Viral and/or bacterial intraocular infections were not observed at all.
Conclusions: Intraocular infections after allo-SCT are currently uncommon due to systematic use of preemptive
treatment regimens, frequent controls, and early treatment of systemic infections.
Keywords: Allogeneic stem cell transplantation, antibiotics, antiviral treatment, ocular infection, prophylactic
treatment
INTRODUCTION
Severe sight-threatening ocular infections can occur
after allogeneic stem cell transplantation (allo-SCT).1
The use of conditioning regimens and immunosup-
pressive drugs improves the overall success rate and
increases the chance of survival after allo-SCT, but
also increases the risk of developing bacterial, viral,
and fungal infections.2,3 After allo-SCT, all patients
receive preventive antibiotic treatment during the
period of immune insufficiency4 and are frequently
assessed for systemic infections and/or reactivations.
There is a lack of available data on the prevalence of
ocular infections after allo-SCT in patients who
received current prophylactic regimens for prevention
of infections. The objective of the present study is to
report on the up-to-date prevalence of intraocular
infections after SCT in the adult population in terms of
the efficacy of the tailored prophylactic regimen.
SUBJECTS AND METHODS
This study was approved by the institutional review
board and is in compliance with the Declaration of
Helsinki.
Correspondence: E. I. Stoyanova, Department of Ophthalmology, University Medical Center Utrecht, Room E 03.136, P.O. Box 85500, 3508 GA
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Patients
In this retrospective cohort study all adult patients
who received allo-SCT between January 2006 and
December 2007 at the University Medical Center
Utrecht (UMCU), The Netherlands, were included.
All patients received ophthalmic examination as part
of an active screening protocol starting 3 months post-
SCT or earlier in the case of ocular complaints or
increased risk of developing an intraocular infection
due to systemic infection. The examination consisted
of registration of ocular and medical history, evalu-
ation of current eye complaints, visual acuity test, slit-
lamp examination with additional fluorescein stain-
ing, intraocular pressure measurement, followed by
Schirmer test with local anesthetic and dilated fundus
examination.
Medical Data
Data collection included demographic characteristics;
cytomegalovirus (CMV) and Epstein-Barr virus
(EBV) serologic status of donors and recipients;
type of immunosuppressive therapy; type of post-
SCT prophylaxis; onset, type, and treatment of sys-
temic and intraocular infections; visual acuity (VA)
during and if applicable after (intra)ocular infection;
additional ocular complications and the presence of
systemic and ocular graft-versus-host disease (GvHD).
If multiple SCTs were performed, the follow-up time
was considered the time between the last allo-SCT and
the last medical assessment at the UMCU.
Post-Transplantation Procedure
The post-SCT immunosuppressive protocol is
described in Table 1. All patients received
co-trimoxazol 480 mg qd and valaciclovir 500 mg bid
for 18 months. Ciproxin 500 mg bid po and flucon-
azole 150 mg qd po were administered during the
post-SCT neutropenic state. Additional antiviral (val-
ganciclovir) and antifungal (voriconazol) treatment
was used in case of infection/reactivation with CMV
and Aspergillus, respectively.
RESULTS
Subjects
A total of 140 patients were included in the study. Five
patients were excluded from the study due to incom-
plete medical records. The basic characteristics of the
study population are described in Table 2. The median
follow-up time was 15 months, ranging from 1 to 74
months. The cause of limited follow-up included
mostly death and in 1 case referral to another hospital
for follow-up. All patients had ocular examination 3
months after allo-SCT, 61/135 (45%) patients received
an ophthalmic examination repeated at 1-year follow-
up and 74/135 (55%) at 2-year follow-up. Seventy
patients (52%) were alive at the time of data analysis.
The median time of all patients who have died was 6
months (range 1–50 months) in comparison to all
living patients, whose median follow-up time was 51
months (range 2–74 months).
Systemic Infectious Sequelae
Fifty-nine patients (44%) developed systemic infec-
tion(s) or reactivations, of which 22 (16%) had simul-
taneously two or more infectious agents (see Table 2).
The median time of development of systemic infection
or reactivation since last-SCT was 2 months (range,
0.03–56.52 months). The most common was CMV
TABLE 1. Immunosuppressive treatment after allogeneic stem cell transplantation (allo-SCT).
Subtype of allo-SCT Immunosuppressive treatment Durations (days)
NMA MUD 1. Cyclosporine 4.5 mg/kg 2/day po 1. D-3 to Dþ 180a
2. Mycophenolate 15 mg/kg 3/day po 2. D0 to Dþ 84b
NMA matched sibling 1. Cyclosporine 6.25 mg/kg 2/day po 1. D-3 to Dþ 180a
2. Mycophenolate 15 mg/kg 3/day po 2. D0 to Dþ 84b
MA MUD and 1. Cyclosporine 1.5 mg/kg/24 h 2/day iv
Cyclosporine 2/day poc
1. D-3 to Dþ 20
Dþ 21 to Dþ 180a
MA matched sibling 2. Mycophenolate 15 mg/kg 3/day iv
Mycophenolate 15 mg/kg 3/day pod
2. D-0 to Dþ 20
Dþ 21 to Dþ 84b
D, day; NMA, nonmyeloablative; MA, myeloablative; MUD, HLA- matched unrelated donor; po, per
os; iv, intravenous.
aAfter Dþ 180 10% weekly dose reduction, if until Dþ 120 no GvHD, reduced in 2 weeks.
bDose reduction in 2 weeks after Dþ 84.
cOral dose adapted according to referential blood values of 0.2–0.4 mg/L.
dMaximal dose mycophenolate 1 g 3/day po.
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reactivation, occurring in 27% of the patients, fol-
lowed by EBV reactivation and/or infection and
Aspergillus pneumoniae, detected in 11% and 9%,
respectively. One patient (1%) with CMV reactivation
was co-infected with human herpes virus type 6
(HHV6). The median reactivation times are described
in Table 3. In 14 patients (10%) the specific origin of
infection was either unknown or of a nonopportunis-
tic origin. None of the patients has developed infec-
tion with Toxoplasma. A total of 105 patients developed
systemic GvHD (78%), of which 45 (33%) had acute
GvHD and 60 chronic GvHD (44%). Of the patients
with systemic opportunistic reactivations or infec-
tions, 84% had concurrent systemic GvHD and 22%
had a concurrent ocular GvHD.
Ocular Infectious Sequelae
Only 1 patient (0.7%) developed an intraocular infec-
tion. The infectious agent was a fungus (Scedosporium
apiospermum) and this infection developed 6 months
after allo-SCT (see selected case report later in the
results section). None of the patients developed
bacterial or viral intraocular infections. Anterior seg-
ment complications included ocular GvHD in 37/135
(27%), consisting of dry eye syndrome in 22 (16%) and
conjunctival involvement in 15/135 (11%).
Two patients developed uveitis, both with negative
intraocular fluid analyses for infectious agents. The
first case of anterior uveitis (0.7%) developed concur-
rently with an exacerbation of chronic GvHD and
diminished quickly with anti-GvHD therapy; in the
other case the patient developed uveitis after radi-
ation therapy. Optic disc edema (ODE) was observed
in 3 patients (2%) and was associated with the
Scedosporium apiospermum chorioretinitis in 1 patient.
In the second case ODE was accompanied by
perimacular puckering OD and was diagnosed using
optical coherence tomography (OCT) and fluorescein
angiography (FAG). During pars plana vitrectomy
(PPV) no infectious agent was found and it was
hypothesized that ODE might be related to cyclospor-
ine medication in this patient. The final VA slightly
improved and remained stable at VA 0.4. In the third
case, the patient’s decreasing VA could not be
explained by the ophthalmic examination findings.
By means of OCT and FAG, ODE and mild unilateral
papillitis were diagnosed. The patient developed
severe systemic GvHD, successfully treated with
high-dose prednisone po. Despite the clinical
improvement of optic disc edema, the vision
remained very low (VA 0.1). The ODE in this patient
was considered idiopathic as we could not identify
any cause of ODE by neurologic examination and
imaging and the patient did not use cyclosporine
medication.
Selected Case Report: Intraocular Infection
with Scedosporium apiospermum
A 59-year-old female suffered from non-Hodgkin
lymphoma for which she underwent myeloablative
matched unrelated donor allo-SCT, secondary to total
body irradiation and chemotherapy. One year later
she was diagnosed with right elbow abscess and
showed osteomyelitis signs and subsequently devel-
oped Scedosporium aspiospermum endocarditis and
parieto-occipital abscess in the left hemisphere.
Simultaneously, the patient developed painless loss
of vision in her right eye and slit-lamp examination
revealed normal anterior segment while active chor-
ioretinal lesion was observed during ophthalmoscopy.
The Scedosporium infection further progressed into a
retinal abscess for which she underwent vitrectomy,
lensectomy, and retinectomy. The final diagnosis of
Scedosporium apiospermum chorioretinitis was con-
firmed from vitreous cultures and the patient was
TABLE 2. Demographic characteristics of allogeneic stem cell
transplantation (allo-SCT) patients.
Males, n (%) 82/135 (61)
Age, median (range) 56.0 (21–73)
Diagnosis, n (%)
ALL 13/135 (10)
CLL 9/135 (7)
AML 35/135 (26)
CML 9/135 (7)
NHL 22/135 (16)
HL 7/135 (5)
MM 25/135 (19)
Other 15/135 (11)
Systemic opportunistic infection/
reactivation, n (%)
59/135 (44)
One agent 37/135 (27)
Two or more agents 22/135 (16)
Follow-up to systemic infection/
reactivation, median months (range)
2.49 (0.03–56.52)
Donor, n (%)
MUD 77/135 (57)
Matched sibling 52/135 (39)
Other 6/135 (5)
ALL, acute lymphatic leukemia; CLL, chronic lymphatic
leukemia, AML, acute myeloid leukemia; CML, chronic mye-
loid leukemia; NHL, non-Hodgkin lymphoma; HL, Hodgkin
lymphoma; MM, multiple myeloma; MUD, HLA-matched
unrelated donor.
TABLE 3. Median interval between last allo-SCT and systemic
reactivation and/or infection(s).
Opportunistic agent
Median in months
(minimum–maximum)
CMV reactivation and/or infection,
n= 36/135 (27%)
1.46 (0.03–56.52)
EBV reactivation and/or infection,
n= 15/135 (11%)
1.77 (0.49–22.43)
Aspergillus pneumoniae, n= 12/135 (9%) 4.46 (0.26–31.44)
CMV, cytomegalovirus; EBV, Epstein-Barr virus.
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treated with amfotericine B and voriconazol. Three
years later her vision was 0.1 in the affected eye due to
inactive retinal scar.
DISCUSSION
Our study documents only 1 case of intraocular
infection during a 2-year follow-up of 135 patients
after allo-SCT; this infection was caused by the fungus
Scedosporium apiospermum. Intraocular bacterial and
viral infections were not observed, nor was intrao-
cular toxoplasmosis diagnosed. The most frequent
ocular sequel of allo-SCT included ocular graft-
versus-host disease which developed in 37/135
patients (27%).
Intraocular infections in immunosuppressed
patients and their dramatic manifestations may lead
to severe visual loss.5 The prevalence of intraocular
infections after solid organ transplants was previously
reported to range from 3 up to 15%.2,6,7 No recent
systematic studies are available on the incidence of
intraocular infections following allo-SCT. One study
reported on a 0.8% incidence of intraocular infections
after allo-SCT; however, this study focused mainly on
ocular GvHD and furthermore its precise follow-up
pattern is not clear.5 CMV infections after allo-SCT
represented the most frequent intraocular infection
(2.2%), followed by EBV (2%) and Toxoplasma gondii
(0.97%).5,8–12 Originally, intraocular CMV retinitis
after allo-SCT was reported to represent a rare
complication with low incidence,13 but Xhaard et al.
reported that implementation of mismatched donor-
ship in allo-SCT has increased the CMV retinitis
incidence more than 10 times.11 The reported cases
also suffered from chronic GvHD, a disease with a
drastically increasing incidence as a result of the
matched unrelated donorship techniques.14 Other
reports also suggest that there is a higher chance of
CMV infection occurring among CMV seronegative
recipients from CMV seropositive donors.11
Up-to-date transplantation centers show a great
variety of immunosuppressive and antimicrobial
regimes in keeping with type, dosage, and duration
of the administered medication, resulting in discrep-
ant incidence reports.4,5,15–17 In our study, we report a
single case of disseminated Scedosporium apiospermum
infection complicated by endocarditis, brain abscess,
and chorioretinitis. From a recently conducted litera-
ture study such filamentous fungi have been related
to poor vision outcomes and low survival rate.18
Previously, McKelvie et al. described 2 patients with
disseminated post-SCT Scedosporium sp. endophthal-
mitis and fungemia, nonresponsive to antifungal
therapy with amphotericin B and fluconazole, that
resulted in death.19 Husain et al. conducted a study in
which voriconazol was related to a lower mortality
rate than amfotericine B or itraconazol.20 Our patient
was successfully treated with a combination of vori-
conazole and amphotericine B combined with surgical
abscess drainage.
Our study reports no intraocular infections due to
viruses or bacteria, which is consistent with an earlier
report that points out that the major cause of post-
transplant systemic infections is due to fungal infec-
tions.15 Although this study was designed in a
retrospective fashion, the strict follow-up procedures
at the hematology and ophthalmology departments
secure a detailed and reliable medical file data
collection in regard to complaints registration and
detection of intraocular infections. The median follow-
up in our study of 15 months allowed an optimal time
for intraocular infections to develop, excluding acute
retinal necrosis and progressive outer retinal necrosis,
which have been documented to develop in most
cases later than 5 years after transplantation.8 In this
study, 19 patients had a post-SCT follow-up time
longer than 5 years and none of them developed these
viral intraocular manifestations.
Our findings of lack of intraocular infections are
consistent with a previous, but independently con-
ducted study by Westeneng et al. in the UMCU21
with a prospectively kept database, in which the
incidence of intraocular infection of unknown origin
was 1.1%.
Our results point out that when preventive anti-
bacterial and antiviral treatment regimens are com-
bined with regular controls for reactivations of
systemic infections and early treatments they effect-
ively decrease the occurrence of intraocular infections.
Although the modern prophylactic protocol is suc-
cessful in reducing the probability of bacterial and
viral infections, the awareness of a possible fungal
intraocular infection and its timely recognition are of
high importance for visual prognosis of post allo-SCT
patients.
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